745,317 Shares in Fulcrum Therapeutics, Inc. $FULC Acquired by Connor Clark & Lunn Investment Management Ltd.

Posted by Francis Steltz on Aug 29th, 2026

Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 745,317 shares of the company’s stock, valued at approximately $2,728,000. Connor Clark & Lunn Investment Management Ltd. owned 0.98% of Fulcrum Therapeutics at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. BlackRock Inc. purchased a new position in shares of Fulcrum Therapeutics during the 2nd quarter worth $32,297,000. Suvretta Capital Management LLC increased its stake in shares of Fulcrum Therapeutics by 21.9% in the 4th quarter. Suvretta Capital Management LLC now owns 6,561,111 shares of the company’s stock worth $74,206,000 after purchasing an additional 1,180,111 shares in the last quarter. Nantahala Capital Management LLC increased its stake in shares of Fulcrum Therapeutics by 8.9% in the 3rd quarter. Nantahala Capital Management LLC now owns 4,670,784 shares of the company’s stock worth $42,971,000 after purchasing an additional 382,485 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its holdings in Fulcrum Therapeutics by 53.0% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,589,000 shares of the company’s stock worth $31,572,000 after purchasing an additional 1,589,000 shares during the period. Finally, Braidwell LP raised its holdings in Fulcrum Therapeutics by 1,294.7% in the 4th quarter. Braidwell LP now owns 3,061,222 shares of the company’s stock worth $34,622,000 after purchasing an additional 2,841,734 shares during the period. 89.83% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Fulcrum Therapeutics

In related news, Director Alan Ezekowitz sold 18,000 shares of the stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $3.65, for a total transaction of $65,700.00. Following the completion of the sale, the director owned 10,927 shares in the company, valued at approximately $39,883.55. This trade represents a 62.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 7.30% of the stock is currently owned by company insiders.

Fulcrum Therapeutics Stock Performance

FULC opened at $3.85 on Friday. The stock has a market cap of $293.75 million, a price-to-earnings ratio of -3.18 and a beta of 3.05. The firm’s fifty day moving average is $3.73 and its 200 day moving average is $6.00. Fulcrum Therapeutics, Inc. has a fifty-two week low of $2.83 and a fifty-two week high of $15.74.

Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.10). On average, equities research analysts predict that Fulcrum Therapeutics, Inc. will post -0.69 earnings per share for the current year.

Analysts Set New Price Targets

FULC has been the topic of several analyst reports. Truist Financial downgraded Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $4.00 target price on the stock. in a research report on Tuesday, June 2nd. Cantor Fitzgerald downgraded Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 2nd. Wall Street Zen raised Fulcrum Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 2nd. Citigroup cut Fulcrum Therapeutics from an “underperform” rating to an “underweight” rating in a research report on Tuesday, June 2nd. Finally, Jefferies Financial Group set a $4.00 price objective on Fulcrum Therapeutics in a research note on Tuesday, June 2nd. One equities research analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and four have issued a Sell rating to the company’s stock. According to MarketBeat, Fulcrum Therapeutics presently has a consensus rating of “Reduce” and an average price target of $8.20.

Get Our Latest Analysis on FULC

About Fulcrum Therapeutics

(Free Report)

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.